Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Growth Metrics

Others

Ligand Pharmaceuticals (LGNYZ) Raw Materials (2023 - 2024)

Historic Raw Materials for Ligand Pharmaceuticals (LGNYZ) over the last 2 years, with Q4 2024 value amounting to $603000.0.

Ligand Pharmaceuticals' Raw Materials rose 4357.14% to $603000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $603000.0, marking a year-over-year increase of 4357.14%. This contributed to the annual value of $603000.0 for FY2024, which is 4357.14% up from last year.
Per Ligand Pharmaceuticals' latest filing, its Raw Materials stood at $603000.0 for Q4 2024, which was up 4357.14% from $2.5 million recorded in Q3 2024.
In the past 5 years, Ligand Pharmaceuticals' Raw Materials registered a high of $2.5 million during Q3 2024, and its lowest value of $420000.0 during Q4 2023.